Mirum Pharmaceuticals, Inc. (MIRM) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Mirum Pharmaceuticals published the results on November 3, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Mirum Pharmaceuticals' diluted loss per share ($0.87) is larger than its basic loss per share ($0.62) because the diluted calculation removes a $16.5 million gain from the change in fair value of the Bluejay indemnification equity holdback liability.
• Mirum completed its acquisition of Bluejay Therapeutics, the developer of brelovitug, on January 23, 2026. Most of the $756.2 million of acquired in-process research and development expense in the first nine months of 2026 was booked in Q1, which is why Q1 2026 shows a loss of $13.43 per share.

Source: Mirum Pharmaceuticals Q3 2026 results, November 3, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Mirum Pharmaceuticals splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Mirum Pharmaceuticals's LIVMARLI revenue was $133 million in Q3 2026, up 45% from $92.2 million in Q3 2025, 72% of total revenue.
• Mirum Pharmaceuticals's Bile Acid Medicines revenue was $52.3 million in Q3 2026, up 28% from $40.8 million in Q3 2025, 28% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Mirum Pharmaceuticals said:

“2026 net product sales guidance increased to $715 million to $720 million”

Source: Mirum Pharmaceuticals Q3 2026 release, Nov 3, 2026.

This is the company's own guidance as of Nov 3, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the MIRM forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenue and diluted EPS, each as first reported in that quarter's release. Mirum's Q4 2025 release printed a Q4 net loss of $5.7 million but a per-share figure only for the full year, so Q4 2025 EPS is left blank.

We do not hold a confirmed date for Mirum Pharmaceuticals's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 3, 2026

Mirum Pharmaceuticals' revenue is all net product sales from rare liver disease medicines: $185.7 million in Q3 2026, up from $133.0 million. LIVMARLI (maralixibat) brought in $133.4 million, 45% more than a year earlier, and the Bile Acid Medicines, CHOLBAM and CTEXLI, $52.3 million, up 28%. (Mirum Pharmaceuticals Q3 2026 release, Nov 3, 2026; Mirum Pharmaceuticals Form 10-Q, Q3 2026, Nov 3, 2026)

Mirum's 10-Q says the $41.2 million rise in LIVMARLI sales came largely from higher US sales for both the ALGS and especially the PFIC indications, and to a lesser extent from rest-of-world sales through direct markets, distributors and license partners. The $11.5 million rise in Bile Acid Medicines came from new patient starts for both CHOLBAM and CTEXLI. (Mirum Pharmaceuticals Form 10-Q, Q3 2026, Nov 3, 2026)

Most of Mirum's sales are in the US. By ship-to location, US product sales were $150.6 million in the quarter and rest of the world $35.1 million, against $103.7 million and $29.3 million a year earlier. (Mirum Pharmaceuticals Form 10-Q, Q3 2026, Nov 3, 2026)

Mirum received FDA approval of ATEBRIOZ (zilurgisertib), licensed from Incyte, for fibrodysplasia ossificans progressiva during the quarter and launched it; the Q3 2026 product sales table has no separate ATEBRIOZ line. Cost of sales rose to $35.2 million from $25.5 million, mainly from $7.7 million higher royalty expenses on LIVMARLI and the Bile Acid Medicines under licensing agreements. (Mirum Pharmaceuticals Q3 2026 release, Nov 3, 2026; Mirum Pharmaceuticals Form 10-Q, Q3 2026, Nov 3, 2026)

Mirum Pharmaceuticals lost $40.8 million in Q3 2026, or $0.87 per diluted share, after net income of $2.9 million, or $0.05 per diluted share, a year earlier. Research and development expense rose to $107.9 million from $43.0 million, including $42.1 million for brelovitug, the hepatitis delta antibody that came with the Bluejay acquisition. Mirum also recorded a $13.5 million acquired IPR&D charge for a clinical stage small molecule licensed from a third party. (Mirum Pharmaceuticals Q3 2026 release, Nov 3, 2026; Mirum Pharmaceuticals Form 10-Q, Q3 2026, Nov 3, 2026)

Mirum's diluted loss per share is larger than its basic loss of $0.62. Other income of $16.4 million was mainly a $16.5 million gain from remeasuring the liability for stock issuable in the Bluejay acquisition, and the diluted calculation takes that gain back out, giving a diluted net loss of $57.3 million. Mirum does not report an adjusted EPS figure in its release; it lists $40.0 million of stock-based compensation, intangible amortization and other non-cash expenses within operating costs. (Mirum Pharmaceuticals Form 10-Q, Q3 2026, Nov 3, 2026; Mirum Pharmaceuticals Q3 2026 release, Nov 3, 2026)

Diluted weighted average shares were 66,049,776, against 56,993,841 a year earlier, after Mirum issued 4,517,062 shares as upfront consideration for Bluejay. Interest expense fell $2.0 million after the exchange and repurchase of part of its 2029 convertible notes; in the quarter Mirum repurchased $20.0 million of those notes, about 25% of what was outstanding. (Mirum Pharmaceuticals Q3 2026 release, Nov 3, 2026; Mirum Pharmaceuticals Form 10-Q, Q3 2026, Nov 3, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Mirum Pharmaceuticals gives a full-year net product sales range and raised it with Q3 2026 results to $715 million to $720 million. Through nine months it has reported $521.8 million of product sales. Mirum does not give EPS or expense guidance in the release. (Mirum Pharmaceuticals Q3 2026 release, Nov 3, 2026; Mirum Pharmaceuticals Form 10-Q, Q3 2026, Nov 3, 2026)

The release lists Mirum's next milestones: brelovitug AZURE-4 Phase 3 topline data in Q4 2026, volixibat VANTAGE Phase 2b data in PBC in Q1 2027, and planned submissions in H1 2027 for volixibat in PSC, the LIVMARLI EXPAND sNDA, the ATEBRIOZ pediatric sNDA and a brelovitug BLA, the last subject to supportive AZURE-4 results. (Mirum Pharmaceuticals Q3 2026 release, Nov 3, 2026)

A consensus figure is the average of the models published by the analysts who cover Mirum Pharmaceuticals, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Mirum Pharmaceuticals's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning MIRM is on is MIRM a buy or a sell?, what analysts expect next is on the MIRM forecast, and what the company does is on the Mirum Pharmaceuticals, Inc. (MIRM) stock page.

Every number on this page can be traced to a document Mirum Pharmaceuticals published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.